We, therefore, sought to comparatively benchmark the previously identified ctDNA methylation marker panel against PSA levels using prostate-specific membrane antigen (PSMA) positron-emission-tomography/computed-tomography (PET/CT), the current imaging gold standard for PCa detection [17] and prognostic in itself [18, 19]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.